Literature DB >> 10521448

Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex.

B Lindahl1, C Westling, G Giménez-Gallego, U Lindahl, M Salmivirta.   

Abstract

Heparan sulfate found in the cerebral plaques of Alzheimer's disease binds to beta-amyloid (Abeta) fibrils. This interaction has been proposed to enhance fibril deposition and mediate Abeta-induced glia activation and neurotoxicity. On the other hand, heparan sulfate augments signaling of fibroblast growth factor-2 (FGF-2), a neuroprotective factor that antagonizes the neurotoxic effects of Abeta. We defined structures in heparan sulfate from human cerebral cortex that bind Abeta fibrils. The minimal binding site is found in N-sulfated hexasaccharide domains and contains critical 2-O-sulfated iduronic acid residues. By contrast, binding of Abeta monomers requires, in addition, 6-O-sulfate groups on glucosamine residues. The binding specificity of fibrillar Abeta is shared by FGF-2, and we here show that cerebral heparan sulfate domains selected for binding to Abeta-(1-40) fibrils bind also to FGF-2. These data suggest that neurotoxic and neuroprotective signals may converge by competing for the same binding sites on the heparan sulfate chain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10521448     DOI: 10.1074/jbc.274.43.30631

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells.

Authors:  Paul O'Callaghan; Elina Sandwall; Jin-Ping Li; Hong Yu; Rivka Ravid; Zhi-Zhong Guan; Toin H van Kuppevelt; Lars N G Nilsson; Martin Ingelsson; Bradley T Hyman; Hannu Kalimo; Ulf Lindahl; Lars Lannfelt; Xiao Zhang
Journal:  Brain Pathol       Date:  2008-04-11       Impact factor: 6.508

Review 2.  The "in and out" of glucosamine 6-O-sulfation: the 6th sense of heparan sulfate.

Authors:  Rana El Masri; Amal Seffouh; Hugues Lortat-Jacob; Romain R Vivès
Journal:  Glycoconj J       Date:  2016-11-03       Impact factor: 2.916

3.  Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site.

Authors:  Z Shriver; R Raman; G Venkataraman; K Drummond; J Turnbull; T Toida; R Linhardt; K Biemann; R Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

4.  Heparin nanoparticles for β amyloid binding and mitigation of β amyloid associated cytotoxicity.

Authors:  Peng Wang; Hovig Kouyoumdjian; David C Zhu; Xuefei Huang
Journal:  Carbohydr Res       Date:  2014-08-02       Impact factor: 2.104

5.  A computational approach for identifying the chemical factors involved in the glycosaminoglycans-mediated acceleration of amyloid fibril formation.

Authors:  Elodie Monsellier; Matteo Ramazzotti; Niccolò Taddei; Fabrizio Chiti
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

6.  HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide.

Authors:  Brian Giunta; Yuyan Zhou; Huayan Hou; Elona Rrapo; Francisco Fernandez; Jun Tan
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

7.  Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.

Authors:  Andrew R Schneider; Youssef Sari
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

8.  Novel glycosaminoglycan precursors as anti-amyloid agents part II.

Authors:  Robert Kisilevsky; Walter A Szarek
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 9.  Heparin oligosaccharides as potential therapeutic agents in senile dementia.

Authors:  Qing Ma; Umberto Cornelli; Israel Hanin; Walter P Jeske; Robert J Linhardt; Jeanine M Walenga; Jawed Fareed; John M Lee
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

10.  Shortening heparan sulfate chains prolongs survival and reduces parenchymal plaques in prion disease caused by mobile, ADAM10-cleaved prions.

Authors:  Patricia Aguilar-Calvo; Alejandro M Sevillano; Jaidev Bapat; Katrin Soldau; Daniel R Sandoval; Hermann C Altmeppen; Luise Linsenmeier; Donald P Pizzo; Michael D Geschwind; Henry Sanchez; Brian S Appleby; Mark L Cohen; Jiri G Safar; Steven D Edland; Markus Glatzel; K Peter R Nilsson; Jeffrey D Esko; Christina J Sigurdson
Journal:  Acta Neuropathol       Date:  2019-10-31       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.